SMARCA5 and ovarian carcinoma: Although not specific to CHD4, Dr. Saunthararajah and his colleagues established a SMARCA5/CHD4 dual inhibitor ED2-AD101 that potently suppressed AML cell growth in cell-based assays [31], which motivated us to investigate whether ED2-AD101 increased the sensitivity of ovarian cancer cells to platinum agents.